EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease

Roos J Jutten iD, Kathryn V Papp, Suzanne Hendrix, Noel Ellison, Jessica B Langbaum, Michael C Donohue, Jason Hassenstab, Paul Maruff, Dorene M Rentz, John Harrison, Jeffrey Cummings, Philip Scheltens und 1 weitere

Alzheimer's & Dementia · 2023-02 · 19 (2) · 708-720

DOI: 10.1002/alz.12773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 10.09.2022. Verfasst von Roos J Jutten und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A crucial aspect of any clinical trial is using the right outcome measure to assess treatment efficacy. Compared to the rapidly evolved understanding and measurement of pathophysiology in preclinical and early symptomatic stages of Alzheimer's disease (AD), relatively less progress has been made in the evolution of clinical outcome assessments (COAs) for those stages. The current paper aims to provide a benchmark for the design and evaluation of COAs for use in early AD trials. We discuss lessons learned on capturing cognitive changes in predementia stages of AD, including challenges when validating novel COAs for those early stages and necessary evidence for their implementation in clinical trials. Moving forward, we propose a multi‐step framework to advance the use of more effective COAs to assess clinically meaningful changes in early AD, which will hopefully contribute to the much‐needed consensus around more appropriate outcome measures to assess clinical efficacy of putative treatments. Highlights We discuss lessons learned on capturing cognitive changes in predementia stages of AD. We propose a framework for the design and evaluation of performance based cognitive tests for use in early AD trials. We provide recommendations to facilitate the implementation of more effective cognitive outcome measures in AD trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansOutcome Assessment, Health CareTreatment OutcomeNeuropsychological TestsCognition

Stichwörter der Autor:innen

Alzheimer's diseaseclinical outcome assessmentsclinical trialcognitionpreclinicalprodromal

Autor:innen und Institutionen

  • Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Pentara Corporation, Salt Lake City, Utah, USA.
  • Banner Alzheimer's Institute, Phoenix, Arizona, USA.
  • Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, California, USA.
  • Knight Alzheimer Disease Research Center, Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.

ORCID-Profile: Roos J Jutten

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Jutten, R. J., Papp, K. V., Hendrix, S., Ellison, N., Langbaum, J. B., Donohue, M. C., Hassenstab, J., Maruff, P., Rentz, D. M., Harrison, J., Cummings, J., Scheltens, P., & Sikkes, S. A. M. (2023). Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease. Alzheimer's & Dementia, 19(2), 708-720. https://doi.org/10.1002/alz.12773

Vancouver

Jutten RJ, Papp KV, Hendrix S, Ellison N, Langbaum JB, Donohue MC, et al. Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease. Alzheimer's & Dementia. 2023;19(2):708-720. doi:10.1002/alz.12773

BibTeX
@article{Jutten2023,
  author = {Jutten, Roos J and Papp, Kathryn V and Hendrix, Suzanne and Ellison, Noel and Langbaum, Jessica B and Donohue, Michael C and Hassenstab, Jason and Maruff, Paul and Rentz, Dorene M and Harrison, John and Cummings, Jeffrey and Scheltens, Philip and Sikkes, Sietske A M},
  title = {Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  volume = {19},
  number = {2},
  pages = {708--720},
  doi = {10.1002/alz.12773}
}
Kostenlos starten →